MGLL and Dravet syndrome: These data show that chronic suppression of MAGL activity may improve behavior and brain functions of Ts65Dn mice and, therefore, pharmacological inhibition of MAGL may be a new approach for the pharmacotherapy of cognitive impairment in DS.